Shots:
- Novo Nordisk has entered into a definitive asset purchase & license agreement with Omeros to develop zaltenibart (MASP-3 inhibitor) for rare blood & kidney disorders, while Omeros retains certain rights to other preclinical MASP-3 programs, incl. small-molecule MASP-3 inhibitors for select indications
- As per the deal, Novo will receive exclusive global rights to develop & commercialize zaltenibart in all indications in exchange for ~$2.1B, incl. $340M in upfront & near-term milestone payments, plus development & commercial milestones, with net sales-based tiered royalties; closing expected in Q4’25
- Zaltenibart (OMS906) will be assessed in a Novo Nordisk-led global P-III program for paroxysmal nocturnal hemoglobinuria & will be further explored in a range of other rare blood & kidney disorders
Ref: Novo Nordisk | Image: Novo Nordisk and Omeros | Press Release
Related News:- Novo Nordisk to Acquire Akero Therapeutics for ~$5.2B, Expanding its MASH Portfolio
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
